Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874276 · ClinicalTrials.gov registry record · NA
Pharmacotoxicology of Trichloroethylene Metabolites
A NA study of Congenital Lactic Acidosis, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00874276: Completed NA study of Congenital Lactic Acidosis, sponsored by University of Florida.
NCT00874276 is a NA study of Congenital Lactic Acidosis that has completed, run by University of Florida. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00874276, a NA study of Congenital Lactic Acidosis, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
To establish the relationship between human MAAI haplotype and DCA and tyrosine metabolism. This aim test the postulates that MAAI haplotype determines, and thus can predict,1) dose-dependent DCA kinetics and biotransformation.
Primary Outcome
Terminal half-life (the amount of time needed to clear one-half of dose of the drug).
Conditions Studied
Interventions
- DRUG Dichloroacetate (DCA)
- GENETIC Genetic Marker on Chromosome 14q24.3
Study Locations (1)
Florida
- University of Florida Shands Hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-11 |
| Phase | NA |
What the finished NCT00874276 record still lists
NCT00874276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Congenital Lactic Acidosis appearing as the primary indexed condition, and to 2 interventions - of which Dichloroacetate (DCA) is the first listed.
NCT00874276 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00874276 about?
NCT00874276 is a clinical study titled "Pharmacotoxicology of Trichloroethylene Metabolites". To establish the relationship between human MAAI haplotype and DCA and tyrosine metabolism. This aim test the postulates that MAAI haplotype determines, and thus can predict,1) dose-dependent DCA kinetics and biotransformation.
What is the current status of trial NCT00874276?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2009-08. Estimated completion is 2012-11.
What conditions does trial NCT00874276 study?
This clinical trial studies the following conditions: Congenital Lactic Acidosis.
What interventions are being tested in trial NCT00874276?
The interventions under investigation include: Dichloroacetate (DCA) (DRUG), Genetic Marker on Chromosome 14q24.3 (GENETIC).
Who is sponsoring clinical trial NCT00874276?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00874276 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00874276's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia